IRT in Infants With Intestinal Perforation
This study is designed to evaluate a novel tool to aid in the diagnosis of intestinal perforation in infants who are at high risk. Analysis of perforation rates of all infants in the three largest participating sites shows that the majority of infants with perforation will do so prior to day of life 21. This study will target the group of infants at highest risk for IP, those with birth weight less than 1000 grams, within the time frame most likely to capture the perforation. Hypothesis: An IRT value exists that can adequately differentiate premature infants with and without intestinal perforation in the first 3 weeks of life.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Immunoreactive Trypsinogen in Infants With Intestinal Perforation|
- To determine the onset and duration of elevation in serum IRT in infants with intestinal perforation. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- Determine if factors other than intestinal perforation affect serum IRT. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
|Study Start Date:||August 2010|
|Estimated Study Completion Date:||August 2014|
|Estimated Primary Completion Date:||September 2013 (Final data collection date for primary outcome measure)|
Weight less than 1000 grams, age 1 - 16 days.
At least 300 infants age 1-16 days will be enrolled. IRT values will be obtained daily through day of life 21, if the infant is already having labs drawn that day. The primary outcomes will be intestinal perforation and/or death on or before day of life 21. Each patient will be followed until death or discharge. Discharge will be defined as the release of the infant to home. Infants who are transferred to another NICU may be followed if the receiving NICU is one of the investigational sites. Transfer includes the release of the infant to outside units or other units within the same hospital. The purpose of this follow up is to obtain serial IRT values through day of life 21.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01530828
|United States, Minnesota|
|Children's Hospitals & Clinics of Minnesota||Recruiting|
|St. Paul, Minnesota, United States, 55102|
|Contact: Pat A Meyers, BS 651-220-6026 email@example.com|
|Sub-Investigator: Mark Bergeron, MD|